Literature DB >> 15567880

Dose-finding study of daily GnRH antagonist for the prevention of premature LH surges in IVF/ICSI patients: optimal changes in LH and progesterone for clinical pregnancy.

Judith A F Huirne1, Andre C D van Loenen, Roel Schats, Joseph McDonnell, Peter G A Hompes, Joop Schoemaker, Roy Homburg, Cornelis B Lambalk.   

Abstract

BACKGROUND: An optimal range of LH concentrations for achieving pregnancy has not been established. The aim of this study was to investigate the effect of various LH levels induced by different GnRH antagonist doses on IVF outcome.
METHODS: This was a prospective, single centre study including 144 IVF patients, stimulated with recombinant FSH from cycle day 2, and co-treated with daily GnRH antagonist (antide/Iturelix) (2 mg/2 ml, 1 mg/ml, 0.5 mg/ml, 0.5 mg/0.5 ml or 0.25 mg/ml) from cycle day 7 onwards. Serum samples were taken three times daily.
RESULTS: Clinical pregnancies were only observed within a particular range of change in LH levels. The upper and lower thresholds for the mean LH area under the curve (AUC), adjusted for the baseline LH level before the antagonist was started (LH AUC(-S6); S6=stimulation day 6) were -2.2 and 12.4 (IU/l) respectively (a negative value=below baseline levels). There were no clinical pregnancies outside these threshold values. Similar results were found for progesterone, the threshold levels of progesterone AUC(-S6) were 3.98 and -1.21 ng/ml. Moreover, there were no pregnancies with progesterone levels >0.26 ng/ml/follicle on the day of hCG.
CONCLUSIONS: Excessive or insufficient suppression of LH and progesterone levels during GnRH antagonist administration and high progesterone/follicle on hCG day seems to be associated with impaired clinical pregnancy rates.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15567880     DOI: 10.1093/humrep/deh601

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  27 in total

1.  GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.

Authors:  Yannis Prapas; Konstantinos Ravanos; Stamatios Petousis; Yannis Panagiotidis; Achilleas Papatheodorou; Chrysoula Margioula-Siarkou; Assunta Iuliano; Giuseppe Gullo; Nikos Prapas
Journal:  J Assist Reprod Genet       Date:  2017-08-03       Impact factor: 3.412

2.  Comparison of embryological and clinical outcome in GnRH antagonist vs. GnRH agonist protocols for in vitro fertilization in PCOS non-obese patients. A prospective randomized study.

Authors:  Rafal Kurzawa; Przemyslaw Ciepiela; Tomasz Baczkowski; Krzysztof Safranow; Pawel Brelik
Journal:  J Assist Reprod Genet       Date:  2008-09-19       Impact factor: 3.412

3.  Influence of GnRH antagonist in reproductive women on in vitro fertilization and embryo transfer in fresh cycles.

Authors:  Yang Xu; Yu-Song Zhang; Dong-Yi Zhu; Xiang-Hong Zhai; Feng-Xia Wu; An-Cong Wang
Journal:  Biomed Rep       Date:  2018-11-29

4.  Association between follicular fluid levels of HMGB1 protein and outcomes in patients undergoing in vitro fertilization/intracytoplasmic sperm injection cycles.

Authors:  Saijiao Li; Tailang Yin; Wei Li; Jing Yang; Wangming Xu; Danni Zhou
Journal:  Exp Ther Med       Date:  2015-03-18       Impact factor: 2.447

5.  The effect of rLH supplementation to the GnRH-antagonist protocol on endocrine dynamics in the advanced reproductive age.

Authors:  J S Younis; I Izhaki; M Ben-Ami
Journal:  J Endocrinol Invest       Date:  2017-03-13       Impact factor: 4.256

6.  Differences in serum LH and FSH levels using depot or daily GnRH agonists in controlled ovarian stimulation: influence on ovarian response and outcome of ART.

Authors:  Barbara Sonntag; Ludwig Kiesel; Eberhard Nieschlag; Hermann M Behre
Journal:  J Assist Reprod Genet       Date:  2005-08       Impact factor: 3.412

7.  IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre-treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study.

Authors:  Hong Ye; Guo-ning Huang; Ping-hong Zeng; Li Pei
Journal:  J Assist Reprod Genet       Date:  2009-02-19       Impact factor: 3.412

8.  Medroxyprogesterone acetate used in ovarian stimulation is associated with reduced mature oocyte retrieval and blastocyst development: a matched cohort study of 825 freeze-all IVF cycles.

Authors:  Kemal Ozgur; Murat Berkkanoglu; Hasan Bulut; Levent Donmez; Kevin Coetzee
Journal:  J Assist Reprod Genet       Date:  2020-07-22       Impact factor: 3.412

9.  Lutropin alpha, recombinant human luteinizing hormone, for the stimulation of follicular development in profoundly LH-deficient hypogonadotropic hypogonadal women: a review.

Authors:  Bernd Th Krause; Ralf Ohlinger; Annette Haase
Journal:  Biologics       Date:  2009-07-13

10.  Optimising Follicular Development, Pituitary Suppression, Triggering and Luteal Phase Support During Assisted Reproductive Technology: A Delphi Consensus.

Authors:  Raoul Orvieto; Christos A Venetis; Human M Fatemi; Thomas D'Hooghe; Robert Fischer; Yulia Koloda; Marcos Horton; Michael Grynberg; Salvatore Longobardi; Sandro C Esteves; Sesh K Sunkara; Yuan Li; Carlo Alviggi
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-10       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.